University of Miami's 2nd Biennial Miami Leukemia Symposium

 

University of Miami's 2nd Biennial Miami Leukemia Symposium
N

2020 Update on BPDCN: Efficacy Analysis of Available Standard Therapies and Novel Therapies in Development

By University of Miami's 2nd Biennial Miami Leukemia Symposium FEATURING Naveen Pemmaraju
By University of Miami's 2nd Biennial Miami Leukemia Symposium FEATURING Naveen Pemmaraju
19 views
October 23, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

37:21
Amgen Sponsorship

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey

Featured Video

07:44
Incyte

Optimizing the Management of Patients with Polycythemia Vera (PV)

Feat. P. Bose, R. Rampal
CML and MPNs: Final Frontiers and New Breakthroughs
21:24

2020 Update on Atypical CML, CMML & CNL: Is There Clinical Benefit t…

University of Miami's 2nd Biennial Miami Leukemia Symposium

J. Tyner

40 views
26:24

2020 Update on CML: What Strategies Can Help Overcome Multi-TKI Resi…

University of Miami's 2nd Biennial Miami Leukemia Symposium

J. Cortés

153 views
25:18

2020 Update on Ph- MPN: What Are the Potential Benefits and Limitati…

University of Miami's 2nd Biennial Miami Leukemia Symposium

O. Odenike

166 views
21:19

2020 Update on BPDCN: Efficacy Analysis of Available Standard Therap…

University of Miami's 2nd Biennial Miami Leukemia Symposium

N. Pemmaraju

19 views